ESMO 2017: Study shows ESMO Magnitude of Benefit Scale can be used to grade orphan drugs

The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a valid tool for grading orphan drugs, according to research presented at the ESMO 2017 Congress in Madrid. The ESMO-MCBS scales the clinical benefit that can be anticipated from new anti-cancer...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2xTNGqe
via IFTTT